<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02794571</url>
  </required_header>
  <id_info>
    <org_study_id>GO30103</org_study_id>
    <secondary_id>2016-000944-33</secondary_id>
    <nct_id>NCT02794571</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab With and Without Chemotherapy in Locally Advanced or Metastatic Tumors</brief_title>
  <official_title>A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MTIG7192A as a Single Agent and in Combination With Atezolizumab Administered With and Without Chemotherapy in Patients With Locally Advanced or Metastatic Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This first-in-human open-label, multicenter, dose-escalation and expansion study is designed
      to evaluate the safety, tolerability, and PK of MTIG7192A alone or in combination with
      atezolizumab administered with and without chemotherapy in participants with locally
      advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist,
      has proven to be ineffective or intolerable, or is considered inappropriate, or for whom a
      clinical trial of an investigational agent is a recognized standard of care.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2016</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>From Baseline to the end of Cycle 1 (up to 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs) Graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0</measure>
    <time_frame>From Baseline up to 90 days after last dose of study treatment or until initiation of another systemic anti-cancer therapy (up to approximately 8 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Cycles with MTIG7192A</measure>
    <time_frame>From Baseline to last dose (up to approximately 8 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ia and Ib: Percentage of Participants with Anti-Drug Antibodies (ADAs) to MTIG7192A</measure>
    <time_frame>Day 1 up to 8 years</time_frame>
    <description>Phase (Ph) 1a: Pre-dose on Day 1, Cycles 1-4, 8, 16, every eight cycles (Q8C), at discontinuation (DC), every 30 days up to 120 days; Phase 1b without Chemotherapy: Pre-dose on Day 1, Cycles 1-4, 8, then Q8C, DC (Cycle length 21 days); Phase 1b (Chemotherapy Cohorts and Q4W): Pre-dose on Day 1, Cycles 1-4, 8, 12 and 16, then DC (Cycle length 21/28 days).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib: Percentage of Participants with ADAs to Atezolizumab</measure>
    <time_frame>Day 1 up to 8 years</time_frame>
    <description>Phase 1b (without Chemotherapy): Pre-dose on Day 1, Cycles 1-4, 8, then Q8C, at DC, every 30 days up to 120 days (Cycle length 21 days); Phase 1b (Chemotherapy Cohorts and Q4W): Pre-dose on Day 1, Cycles 1-4, 8, 12 and 16, then DC (Cycle length 21/28 days).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve (AUC) of MTIG7192A</measure>
    <time_frame>Day 1 up to 8 years</time_frame>
    <description>During Phase Ia and Phase Ib dose-escalation stages time frame is as follows: Pre-dose Day 1,Cycles 1-4, 8; Cycle 1: Post-dose-0.5 hour (h), 24 h, Days 8 and 15; Day 1, Cycles 2-7 (Ph 1a), Cycles 2, 3, 4 ,8, 16 -0.5 h post-dose; ph1a and 1b - Q8C, DC; every 30 days up to 120 days.
During Phase Ia dose-expansion stage and Phase Ib dose-expansion stages with and without chemotherapy time frame is as follows: Pre-dose Day 1,Cycles 1-4, 8; Cycle 1: Post-dose-0.5 hour (h), 24 h, Days 8 and 15; Day 1, Cycles 2, 3, 4, 8, 12* 16 (C12* only applicable to Q4W and Chemotherapy cohorts): 0.5 h post-dose; ph1a and 1b (Q3W)- Q8C, DC; every 30 days up to 120 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of MTIG7192A</measure>
    <time_frame>Day 1 up to 8 years</time_frame>
    <description>During Phase Ia and Phase Ib dose-escalation stages time frame is as follows: Pre-dose Day 1,Cycles 1-4, 8; Cycle 1: Post-dose-0.5 hour (h), 24 h, Days 8 and 15; Day 1, Cycles 2-7 (Ph 1a), Cycles 2, 3, 4 ,8, 16 -0.5 h post-dose; ph1a and 1b - Q8C, DC; every 30 days up to 120 days.
During Phase Ia dose-expansion stage and Phase Ib dose-expansion stages with and without chemotherapy time frame is as follows: Pre-dose Day 1,Cycles 1-4, 8; Cycle 1: Post-dose-0.5 hour (h), 24 h, Days 8 and 15; Day 1, Cycles 2, 3, 4, 8, 12* 16 (C12* only applicable to Q4W and Chemotherapy cohorts): 0.5 h post-dose; ph1a and 1b (Q3W)- Q8C, DC; every 30 days up to 120 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Serum Concentration (Cmin) of MTIG7192A</measure>
    <time_frame>Day 1 up to 8 years</time_frame>
    <description>During Phase Ia and Phase Ib dose-escalation stages time frame is as follows: Pre-dose Day 1,Cycles 1-4, 8; Cycle 1: Post-dose-0.5 hour (h), 24 h, Days 8 and 15; Day 1, Cycles 2-7 (Ph 1a), Cycles 2, 3, 4 ,8, 16 -0.5 h post-dose; ph1a and 1b - Q8C, DC; every 30 days up to 120 days.
During Phase Ia dose-expansion stage and Phase Ib dose-expansion stages with and without chemotherapy time frame is as follows: Pre-dose Day 1,Cycles 1-4, 8; Cycle 1: Post-dose-0.5 hour (h), 24 h, Days 8 and 15; Day 1, Cycles 2, 3, 4, 8, 12* 16 (C12* only applicable to Q4W and Chemotherapy cohorts): 0.5 h post-dose; ph1a and 1b (Q3W)- Q8C, DC; every 30 days up to 120 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of MTIG7192A</measure>
    <time_frame>Day 1 up to 8 years</time_frame>
    <description>During Phase Ia and Phase Ib dose-escalation stages time frame is as follows: Pre-dose Day 1,Cycles 1-4, 8; Cycle 1: Post-dose-0.5 hour (h), 24 h, Days 8 and 15; Day 1, Cycles 2-7 (Ph 1a), Cycles 2, 3, 4 ,8, 16 -0.5 h post-dose; ph1a and 1b - Q8C, DC; every 30 days up to 120 days.
During Phase Ia dose-expansion stage and Phase Ib dose-expansion stages with and without chemotherapy time frame is as follows: Pre-dose Day 1,Cycles 1-4, 8; Cycle 1: Post-dose-0.5 hour (h), 24 h, Days 8 and 15; Day 1, Cycles 2, 3, 4, 8, 12* 16 (C12* only applicable to Q4W and Chemotherapy cohorts): 0.5 h post-dose; ph1a and 1b (Q3W)- Q8C, DC; every 30 days up to 120 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) of MTIG7192A</measure>
    <time_frame>Day 1 up to 8 years</time_frame>
    <description>During Phase Ia and Phase Ib dose-escalation stages time frame is as follows: Pre-dose Day 1,Cycles 1-4, 8; Cycle 1: Post-dose-0.5 hour (h), 24 h, Days 8 and 15; Day 1, Cycles 2-7 (Ph 1a), Cycles 2, 3, 4 ,8, 16 -0.5 h post-dose; ph1a and 1b - Q8C, DC; every 30 days up to 120 days.
During Phase Ia dose-expansion stage and Phase Ib dose-expansion stages with and without chemotherapy time frame is as follows: Pre-dose Day 1,Cycles 1-4, 8; Cycle 1: Post-dose-0.5 hour (h), 24 h, Days 8 and 15; Day 1, Cycles 2, 3, 4, 8, 12* 16 (C12* only applicable to Q4W and Chemotherapy cohorts): 0.5 h post-dose; ph1a and 1b (Q3W)- Q8C, DC; every 30 days up to 120 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Atezolizumab</measure>
    <time_frame>Day 1 up to 8 years</time_frame>
    <description>During Phase Ib dose-escalation stage time frame will be as follows: Pre-dose Day 1,Cycles 1-4, 8; Cycle 1: Post-dose-0.5 hour (h), 24 h, Days 8 and 15; Day 1, Cycles 2 ,3, 4, 8, 16: 0.5 h post-dose; Q8C, DC; every 30 days up to 120 days.
During Phase Ib dose-expansion stages time frame will be as follows: Pre-dose on Day 1 of Cycles 1-4,8, 12*, 16 (C12* only applicable to Q4W and Chemotherapy cohorts); Post-dose (0.5 h or 24h), on Day 1 of Cycles 1-4, 8, 12, 16; then Q8C until/at DC, every 30 days up to 120 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin of Atezolizumab</measure>
    <time_frame>Day 1 up to 8 years</time_frame>
    <description>During Phase Ib dose-escalation stage time frame will be as follows: Pre-dose Day 1,Cycles 1-4, 8; Cycle 1: Post-dose-0.5 hour (h), 24 h, Days 8 and 15; Day 1, Cycles 2 ,3, 4, 8, 16: 0.5 h post-dose; Q8C, DC; every 30 days up to 120 days.
During Phase Ib dose-expansion stages time frame will be as follows: Pre-dose on Day 1 of Cycles 1-4,8, 12*, 16 (C12* only applicable to Q4W and Chemotherapy cohorts); Post-dose (0.5 h or 24h), on Day 1 of Cycles 1-4, 8, 12, 16; then Q8C until/at DC, every 30 days up to 120 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Cisplatin</measure>
    <time_frame>Pre-dose (5 min) and post-dose (1 h) on Day 1 of Cycles 1 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Carboplatin</measure>
    <time_frame>Pre-dose (5 min) and post-dose (1 h) on Day 1 of Cycles 1 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Pemetrexed</measure>
    <time_frame>Pre-dose (5 min) and post-dose (1 h) on Day 1 of Cycles 1 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Paclitaxel</measure>
    <time_frame>Pre-dose (5 min) and post-dose (1 h) on Day 1 of Cycles 1 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Etoposide</measure>
    <time_frame>Pre-dose (5 min) and post-dose (1 h) on Day 1 of Cycles 1 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1</measure>
    <time_frame>From Baseline until disease progression (up to 8 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response (DOR) According to RECIST Version 1.1</measure>
    <time_frame>From Baseline until disease progression (up to 8 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) According to RECIST Version 1.1</measure>
    <time_frame>From Baseline until disease progression (up to 8 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) According to RECIST Version 1.1</measure>
    <time_frame>Baseline until death from any cause (up to approximately 8 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Advanced/Metastatic Tumors</condition>
  <arm_group>
    <arm_group_label>Phase Ia Dose-Escalation Stage: MTIG7192A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts of at least 3 participants each will be treated with escalating doses of MTIG7192A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase Ia Dose-Expansion Stage: MTIG7192A+Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated with MTIG7192A at or below the maximum tolerated dose (MTD) or maximum administered dose (MAD) in the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase Ib Q3W Dose-Escalation Stage: MTIG7192A+Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A minimum of 3 participants will be treated for each dose level of MTIG7192A in combination with a fixed dose of atezolizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase Ib Q3W Dose-Expansion Stage: MTIG7192A+Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated every 3 weeks (Q3W) with MTIG7192A at or below the MTD or MAD in combination with a fixed dose of atezolizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase Ib Chemotherapy Dose-Expansion Stage: Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Cohort A, carboplatin or cisplatin and pemetrexed chemotherapy will be administered after atezolizumab and MTIG7192A IV infusion. During induction phase, participants will receive atezolizumab and MTIG7192A in combination with carboplatin or cisplatin and pemetrexed on Day 1 of each 21-day cycle for 4 to 6 cycles. During maintenance phase, participants will receive atezolizumab and MTIG7192A in combination with pemetrexed on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase Ib Chemotherapy Dose-Expansion Stage: Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Cohort B, carboplatin and paclitaxel chemotherapy will be administered after atezolizumab and MTIG7192A IV infusion. During induction phase, participants will receive atezolizumab and MTIG7192A in combination with carboplatin and paclitaxel on Day 1 of each 21-day cycle for 4 to 6 cycles. During maintenance phase, participants will receive atezolizumab and MTIG7192A on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase Ib Chemotherapy Dose-Expansion Stage: Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Cohort C, carboplatin or cisplatin and etoposide chemotherapy will be administered after atezolizumab and MTIG7192A IV infusion. During induction phase, participants will receive atezolizumab and MTIG7192A in combination with carboplatin or cisplatin on Day 1 of each 21-day cycle and etoposide on Day 1 to 3 of each 21-day cycle for 4 cycles. During maintenance phase, participants will receive atezolizumab and MTIG7192A on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase Ib Q4W Dose-Expansion Stage: MTIG7192A + Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated every 4 weeks (Q4W) with fixed doses of MTIG7192A and atezolizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle (phase Ib dose-escalation, Q3W dose-expansion and chemotherapy dose-expansion cohorts) and atezolizumab at dose 1680 mg IV will be administered on Day 1 of each 28-day cycle (phase Ib Q4W dose-expansion).</description>
    <arm_group_label>Phase Ib Chemotherapy Dose-Expansion Stage: Cohort A</arm_group_label>
    <arm_group_label>Phase Ib Chemotherapy Dose-Expansion Stage: Cohort B</arm_group_label>
    <arm_group_label>Phase Ib Chemotherapy Dose-Expansion Stage: Cohort C</arm_group_label>
    <arm_group_label>Phase Ib Q3W Dose-Escalation Stage: MTIG7192A+Atezolizumab</arm_group_label>
    <arm_group_label>Phase Ib Q3W Dose-Expansion Stage: MTIG7192A+Atezolizumab</arm_group_label>
    <arm_group_label>Phase Ib Q4W Dose-Expansion Stage: MTIG7192A + Atezolizumab</arm_group_label>
    <other_name>MPDL3280A</other_name>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTIG7192A</intervention_name>
    <description>Several dose levels will be evaluated for MTIG7192A administered as a single agent and in combination with atezolizumab with and without chemotherapy. MTIG7192A will be given via intravenous (IV) infusion on Day 1 of each cycle (21-day cycle for phase Ia and Ib dose escalation, phase Ia dose-expansion, phase Ib Q3W dose-expansion and phase 1b chemotherapy dose-expansion cohorts; and 28-day cycle for phase Ib Q4W dose-expansion) until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent MTIG7192A may receive combination treatment with MTIG7192A and atezolizumab with and without chemotherapy. Combination treatment may continue until disease progression or loss of clinical benefit.</description>
    <arm_group_label>Phase Ia Dose-Escalation Stage: MTIG7192A</arm_group_label>
    <arm_group_label>Phase Ia Dose-Expansion Stage: MTIG7192A+Atezolizumab</arm_group_label>
    <arm_group_label>Phase Ib Chemotherapy Dose-Expansion Stage: Cohort A</arm_group_label>
    <arm_group_label>Phase Ib Chemotherapy Dose-Expansion Stage: Cohort B</arm_group_label>
    <arm_group_label>Phase Ib Chemotherapy Dose-Expansion Stage: Cohort C</arm_group_label>
    <arm_group_label>Phase Ib Q3W Dose-Escalation Stage: MTIG7192A+Atezolizumab</arm_group_label>
    <arm_group_label>Phase Ib Q3W Dose-Expansion Stage: MTIG7192A+Atezolizumab</arm_group_label>
    <arm_group_label>Phase Ib Q4W Dose-Expansion Stage: MTIG7192A + Atezolizumab</arm_group_label>
    <other_name>RO7092284</other_name>
    <other_name>tiragolumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin, AUC of 6 milligram per milliliter per minute (mg/ml/min) for Cohorts A and B and AUC of 5 mg/ml/min for Cohort C, IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment of atezolizumab and MTIG7192A IV infusion.</description>
    <arm_group_label>Phase Ib Chemotherapy Dose-Expansion Stage: Cohort A</arm_group_label>
    <arm_group_label>Phase Ib Chemotherapy Dose-Expansion Stage: Cohort B</arm_group_label>
    <arm_group_label>Phase Ib Chemotherapy Dose-Expansion Stage: Cohort C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 75 milligram per square meter (mg/m^2) IV infusion will be administered on day 1 of each 21-day cycle after combination treatment of atezolizumab and MTIG7192A</description>
    <arm_group_label>Phase Ib Chemotherapy Dose-Expansion Stage: Cohort A</arm_group_label>
    <arm_group_label>Phase Ib Chemotherapy Dose-Expansion Stage: Cohort C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed 500 mg/m^2 IV infusion will be administered on Day 1 of each 21-day cycle after carboplatin or cisplatin IV infusion with combination treatment of atezolizumab and MTIG7192.</description>
    <arm_group_label>Phase Ib Chemotherapy Dose-Expansion Stage: Cohort A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 200 mg/m^2 IV infusion on Day 1 of each 21-day cycle after combination treatment with atezolizumab and MTIG7192A.</description>
    <arm_group_label>Phase Ib Chemotherapy Dose-Expansion Stage: Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide 100 mg/m^2 IV infusion on Days 1, 2, 3 Q3W in 21-day cycle with combination treatment of atezolizumab and MTIG7192.</description>
    <arm_group_label>Phase Ib Chemotherapy Dose-Expansion Stage: Cohort C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 18 years of age or older

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Life expectancy at least 12 weeks

          -  Adequate hematologic and end organ function

          -  Histologic documentation of locally advanced, recurrent, or metastatic incurable
             malignancy that has progressed after at least one available standard therapy; or for
             which standard therapy has proven ineffective, intolerable, or considered
             inappropriate; or for which a clinical trial of an investigational agent is a
             recognized standard of care

          -  Confirmed availability of representative tumor specimens

          -  Measurable disease according to RECIST Version 1.1

        Exclusion Criteria:

          -  Any anti-cancer therapy, whether investigational or approved, including chemotherapy,
             hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study
             treatment

          -  Malignancies other than disease under study within 5 years prior to Day 1 of Cycle 1

          -  Primary central nervous system (CNS) malignancy, or untreated/active CNS metastases

          -  Leptomeningeal disease

          -  History of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia, or
             evidence of active pneumonitis on Screening chest computed tomograph (CT) scan

          -  History of autoimmune disease

          -  Positive human immunodeficiency virus (HIV) test

          -  Active hepatitis B or C, or tuberculosis

          -  Severe infection within 4 weeks prior to randomization

          -  Prior allogeneic bone marrow or solid organ transplant

          -  Significant cardiovascular disease

          -  Known clinically significant liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO30103 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Honor Health Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045-2517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uni of Pittsburgh Cancer Inst. ; Oncology</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital; Pharmacy Department</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Onc., PLLC - SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kinghorn Cancer Centre; St Vincents Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Center</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4X 1K9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie CLCC Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud; Departement Oncologie Medicale</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ICO L'Hospitalet; Servicio de oncologia medica</name>
      <address>
        <city>L Hospitalet De Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra; Servicio de oncología</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Vall d'Hebron; Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro-CIOCC; Oncología Médica</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 6, 2016</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2016</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

